Background {#Sec1}
==========

The continuing changes in global population and epidemiology indicate that the burden of cancer will continue to increase in the coming decades. Cancer is considered as a multifactorial disease and its occurrence is associated with several factors such as lifestyle, environment and single nucleotide polymorphism (SNP) \[[@CR1]--[@CR3]\]. With the remarkable development of a series of genotyping technologies including genome-wide association studies (GWAS), our understanding of genetic factors related to carcinogenesis has substantially expanded \[[@CR4]--[@CR6]\]. Wnt/β-catenin signaling pathway is known to play a central role in the process of embryogenesis, and abnormalities of this pathway are associated with numerous human malignant tumors \[[@CR7], [@CR8]\]. Axin2 protein acts as a negative regulator of Wnt pathway and plays a crucial role in cell differentiation, migration, cytometaplasia, and apoptosis \[[@CR9]--[@CR11]\]. Axin2 protein is also involved in down-regulation of β-catenin translocation ito the nucleus. In this process, Axin2 binds to transcription factors and subsequently inhibits the expression of numerous target genes including *vascular matrix metalloproteinases* (*MMP*), *cox 2*, and *endothelial growth factor* (*VEGF*) \[[@CR12], [@CR13]\].

Mutations of *AXIN2* gene has been identified by previous genotyping technologies. This gene is located on human chromosome 17q23-q24 and composed of 10 exons, which encodes a protein consisting of 843 amino acids \[[@CR14]\]. Loss of heterozygosity of this gene was previously identified in a number of carcinomas such as hepatoblastoma, hepatocellular carcinoma, melanoma, gastrointestinal, ovarian, synchronous endometrial carcinomas \[[@CR15]--[@CR18]\]. Association between AXIN2 variants and carcinoma susceptibility has also been reported by previous publications. These SNPs including: 148 C\>T (rs2240308), 1365 C/T (rs9915936), and rs4791171 A/G (NC_000017.10) \[[@CR19]--[@CR24]\]. Study population of these genetic variants has involved numerous ethnicities such as Brazilians, Iranians, Chinese, Saudi Arabians, Indians and Poles \[[@CR20]--[@CR27]\]. These studies also evaluated various malignancies; nevertheless, there were ambiguous conclusions on the relationship between the *AXIN2* polymorphisms and cancer risk among different case--control studies.

For *AXIN2* 148 C\>T polymorphism, a case--control study observed no statistically significant correlation between controls and prostate adenocarcinoma in Turkish population \[[@CR27]\]. However, another two studies identified notable decreased risks in Iranian colorectal cancer subjects and Chinese prostate adenocarcinoma participants \[[@CR21], [@CR22]\]. Therefore, a meta analysis with all eligible data based on the inclusion criteria was conducted to further assess the associations between *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G polymorphisms and cancer risk \[[@CR19]--[@CR33]\].

Materials and methods {#Sec2}
=====================

Literature retrieval strategy {#Sec3}
-----------------------------

PubMed, Web of Science, Google Scholar, and China Wanfang Databases were systematically searched to identify all eligible published articles on *AXIN2* variants and cancer susceptibility. The following terms were utilized for searching abstracts and titles: "Axin OR *AXIN2*", "polymorphism OR SNP OR variant", and "cancer OR adenocarcinoma OR carcinoma OR tumor". The latest search was conducted on Jan 31, 2019 with no language restrictions. Furthermore, we also carefully screened and manually searched the review or original publications for more eligible studies.

Study selection {#Sec4}
---------------

Two authors independently chose the eligible studies based on the inclusion criteria: (a) case--control studies that evaluated the association between *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G variants and cancer risk; (b) studies that involved available information for measuring odds ratio (OR) with 95% confidence intervals (CIs); (c) genotype distribution in controls must be conformed to Hardy-Weinberg equilibrium (HWE).

Data extraction {#Sec5}
---------------

All related information was independently screened by two investigators (L Shi and B Xu) from each enrolled study, including the name of first author, year of publication, country of origin, ethnicity, source of control, genotyping method, cancer type, total number of participants, *P* value for HWE, age range, genotyping data of *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G variants in cases and controls. Disagreement should be resolved by discussion with a third author (W Zhang). If the controversial content still existed, it should be addressed by all investigators to reach a consensus.

Statistical analysis {#Sec6}
--------------------

The strength of the relationship between *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G polymorphisms and cancer susceptibility was measured by calculating OR with 95% CI. A total of four genetic models were adopted in the current analysis, including allelic comparison model (M-allele vs. W-allele), homozygote contrast model (MM vs. WW), heterozygote model (MW vs. WW), and dominant model (MM + MW vs. WW). The χ^2^-test-based *Q* test was performed to investigate *P* value for heterogeneity among eligible researches. If *P* \< 0.05, indicating that a significant heterogeneity was found, we employed the random-effects model (DerSimonian--Laird method) \[[@CR34]\]. On the other hand, the fixed-effects model (Mantel--Haenszel method) was carried out \[[@CR35]\]. We adopted qualitative funnel plot to assess possible publication bias by calculating the standard error of log(OR) for each research plotted against its log(OR). We further conducted quantitative Egger's test to evaluate funnel plot asymmetry \[[@CR36]\]. The web-based program was applied to check for deviations from the Hardy--Weinberg equilibrium (HWE) of distribution frequencies (<http://ihg2.helmholtz-muenchen.de/cgibin/hw/hwa1.pl>) \[[@CR37]\]. The *P* value more than 0.05 suggested an HWE balance. Moreover, we applied leave-one-out sensitivity analyses to calculate the stability of pooled results \[[@CR38]\]. All of the above analyses were conducted by STATA software v11.0 (Stata Corporation, TX).

In silico analysis of *AXIN2* expression {#Sec7}
----------------------------------------

An online gene expression database was adopted to investigate the *AXIN2* expression in lung and prostate adenocarcinoma tissues and the paracancerous tissues. (<http://gemini.cancer-pku.cn/>) \[[@CR39]\]. RNA expression profiles of 446 pathologically diagnosed lung adenocarcinoma (including 387 Caucasians, 51 African-Americans, and 8 Asians) and 153 prostate adenocarcinoma tissues (containing 147 Caucasians and 6 African-Americans) were evaluated by this database. The Cancer Genome Atlas (TCGA) samples were also utilized to investigate the high and low expression of *AXIN2* on cancer susceptibility and overall survival time. Moreover, the String online server was applied to assess the gene--gene correlation of *AXIN2* (<http://string-db.org/>).

Results {#Sec8}
=======

Characteristics of studies {#Sec9}
--------------------------

As was shown in Table [1](#Tab1){ref-type="table"}, 15 articles were finally retrieved in the present analysis, which contains 22 case--control studies for *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G variants. There were 2909 cancer subjects and 2907 control volunteers for 148 C/T polymorphism, 587 cancer subjects and 605 controls for 1365 C/T variant, 785 cases and 443 controls for rs4791171 A/G variant. Furthermore, we checked the minor allele frequencies (MAF) of three *AXIN2* variants by Trans-Omics for Precision Medicine (TOPMed) online (<https://www.ncbi.nlm.nih.gov/snp/>) (Fig. [1](#Fig1){ref-type="fig"}). MAF of *AXIN2* 148 C/T were: in Africans, 0.119; Asians, 0.426; Europeans, 0.526; Americans, 0.561; others (including Pacific Islanders), 0.470; Global, 0.474. MAF of *AXIN2* 1365 C/T were: in Africans, 0.069; East Asians, 0.192; Europeans, 0.114; Americans, 0.100; others, 0.090; Global, 0.104. Finally, MAF of *AXIN2* rs4791171 A/G were: in Africans, 0.267; East Asians, 0.370; Europeans, 0.681; Americans, 0.620; others, 0.670; Global, 0.547. In stratified analysis by ethnicity, seven studies were performed in Caucasian populations, twelve studies were in Asian descendants, and two were done in Arabians and one was in Latin descendants. Eight studies were conducted using population based controls and the rest 14 studies were utilizing hospital based controls. The classical genotyping method, PCR-restriction fragment length polymorphism (RFLP) was adopted in nine of these studies.Table 1Basic information for included studies of the correlation between *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G variations and cancer riskAuthor/yearOriginEthnicitySourceCancerMethodAge rangeAge rangeCaseControlCaseControlHWE148 C/TCaseControlTTTCCCTTTCCCKanzaki 2006 \[[@CR26]\]JapanAsianPBLCPCR--RFLP66.4 (mean)NA160109871811552420.863Kanzaki 2006 \[[@CR26]\]JapanAsianPBHNCPCR--RFLP66.4 (mean)NA63109929251552420.863Kanzaki 2006 \[[@CR26]\]JapanAsianPBCRCPCR--RFLP66.4 (mean)NA1131091544541552420.863Gunes 2009 \[[@CR19]\]TurkeyCaucasianPBLCPCR59.22 ± 9.6357.01 ± 7.89100100847451652320.501Gunes 2010 \[[@CR25]\]TurkeyCaucasianHBATPCR58.66 ± 8.0457.01 ± 7.891001001645391652320.501 Pinarbasi 2011 \[[@CR27]\]TurkeyCaucasianHBPCPCR70.38 ± 7.7868.55 ± 4.47841001935301848340.883Naghibal 2012 \[[@CR21]\]IranAsianHBCRCPCR--RFLPNANA1101791957342698550.096Liu 2014 \[[@CR28]\]ChinaAsianPBLCRT-PCR57.78 ± 9.8952.21 ± 10.5649853347216235672552110.457Ma 2014 \[[@CR22]\]ChinaAsianPBPCPCR71.2 (mean)70.4 (mean)103100113161952390.153Mostowska 2014 \[[@CR24]\]PolandCaucasianHBOCPCR--RFLP58.4 ± 9.757.4 ± 7.5228282461156765146710.546Yadav 2016 \[[@CR23]\]IndiaAsianHBGBCTaqman52.05 ± 10.0643.2 ± 11.556425011925319244108980.138Liu 2016 \[[@CR32]\]ChinaAsianHBPTCMassARRAY45.13 ± 10.9741.9 ± 10.22535022427429170.084Kim 2016 \[[@CR31]\]KoreaAsianHBHCCGoldengate53.8 ± 10.341.1 ± 10.324248218100124411952460.789Rosales 2016 \[[@CR29]\]MexicoLatinPBCRCPCR--RFLP59.03 (mean)36.88 (mean)1889954109251859220.054Bahl 2017 \[[@CR30]\]IndiaAsianHBLCPCR--RFLP57.38 ± 10.7453.23 ± 10.44303305541509980144810.3301365 C/TTTTCCCTTTCCCBahl 2017 \[[@CR30]\]IndiaAsianHBLCPCR--RFLP57.38 ± 10.7453.23 ± 10.443033056292685512490.215Pinarbasi 2011 \[[@CR27]\]TurkeyCaucasianHBPCPCR70.38 ± 7.7868.55 ± 4.4784100077708920.677Gunes 2010 \[[@CR25]\]TurkeyCaucasianHBATPCR58.66 ± 8.03957.01 ± 7.891001000991012880.523Gunes 2009 \[[@CR19]\]TurkeyCaucasianPBLCPCR59.22 ± 9.6357.01 ± 7.891001000991012880.523rs4791171A/GGGGAAAGGGAAAAlanazi 2013 \[[@CR20]\]SaudiArabianHBBCRT-PCR48.0 (mean)NA99832144341744220.559Yadav 2016 \[[@CR23]\]IndiaAsianHBGBCPCR--RFLP52.05 ± 10.0643.2 ± 11.55642502282488897118350.926Parine 2019  \[[@CR33]\]SaudiArabianHBCRCTaqMan57.0 (mean)NA1221102755402448380.236*HB* hospital-based, *PB* population-based, *AT* astrocytoma, *BC* breast cancer, *CRC* colorectal cancer, *GBC* gallbladder cancer, *PCR--RFLP* polymerase chain reaction and restrictive fragment length polymorphism, *RT* real time, *NA* not available, *NOS* Newcastle--Ottawa Scale, *HCC* hepatocellular carcinoma, *HNC* head and neck cancer, *HWE* Hardy--Weinberg equilibrium of controls, *LC* lung adenocarcinoma, *PC* prostate adenocarcinoma, *PTC* papillary thyroid carcinoma, *OC* ovarian cancer Fig. 1Minor allele and major allele frequencies for *AXIN2* 148 C/T (**a**), 1365 C/T (**b**), and rs4791171 A/G (**c**) variants in controls stratified by ethnicity. Vertical line, allele frequency; Horizontal line, allele type

Quantitative synthesis {#Sec10}
----------------------

In the overall analysis, we identified a significant correlation between *AXIN2* 148 C/T variant and cancer risk (allele contrast: OR = 0.88, 95% CI 0.77--0.99, *P*~heterogeneity~ = 0.004, *P* = 0.041; heterozygote comparison: OR = 0.84, 95% CI 0.75--0.95, *P*~heterogeneity~ = 0.112, *P* = 0.004; dominant genetic model: OR = 0.82, 95% CI 0.69--0.96, *P*~heterogeneity~ = 0.022, *P* = 0.015) (Table [2](#Tab2){ref-type="table"}). In subgroup analysis by race, we observed positive results in Asians (allele contrast: OR = 0.85, 95% CI 0.73--0.98, *P*~heterogeneity~ = 0.016, *P* = 0.027; dominant genetic model: OR = 0.80, 95% CI 0.66--0.96, *P*~heterogeneity~ = 0.030, *P* = 0.020) and Caucasians (dominant genetic model: OR = 0.76, 95% CI 0.59--0.98, *P*~heterogeneity~ = 0.701, *P* = 0.036), (Fig. [2](#Fig2){ref-type="fig"}). Moreover, subgroup analysis by cancer type suggested that 148 C/T variant was associated with a decreased cancer risk in lung adenocarcinoma (allele contrast: OR = 0.74, 95% CI 0.65--0.84, *P* value for heterogeneity = 0.602, *P* \< 0.001; dominant genetic model: OR = 0.70, 95% CI 0.59--0.84, *P*~heterogeneity~ = 0.803, *P* \< 0.001, Fig. [3](#Fig3){ref-type="fig"}). Similar finding was indicated in prostate adenocarcinoma (heterozygote comparison: OR = 0.54, 95% CI 0.35--0.84, *P*~heterogeneity~ = 0.088, *P* = 0.006; dominant genetic model: OR = 0.62, 95% CI 0.41--0.93, *P*~heterogeneity~ = 0.078, *P* = 0.022). In subgroup analysis by source of control, similar results were also observed in population-based studies. Furthermore, we identified notable correlation between *AXIN2* 1365 C/T variant and cancer risk (allele contrast: OR = 0.71, 95% CI 0.61--0.98, *P*~heterogeneity~ = 0.873, *P* = 0.038; heterozygote comparison: OR = 0.63, 95% CI 0.44--0.91, *P*~heterogeneity~ = 0.668, *P* = 0.014; dominant model: OR = 0.66, 95% CI 0.47--0.94, *P*~heterogeneity~ = 0.775, *P* = 0.021). For rs4791171 A/G polymorphism, no significant association was indicated (allele comparison, OR = 0.99, 95% CI 0.85--1.17, *P*~heterogeneity~ = 0.786, *P* = 0.864; homozygote contrast, OR = 0.94, 95% CI 0.66--1.33, *P*~heterogeneity~ = 0.873, *P* = 0.728; heterozygote contrast, OR = 0.86, 95% CI 0.62--1.17, *P*~heterogeneity~ = 0.522, *P* = 0.322; dominant model, OR = 0.89, 95% CI 0.66--1.19, *P*~heterogeneity~ = 0.575, *P* = 0.429).Table 2Stratified analyses of *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G variants on overall cancer riskVariablesNCase/controlOR (95% CI)*P* ~h~*P*OR (95% CI)*P* ~h~*P*OR (95% CI)*P* ~h~*P*OR (95% CI)*P* ~h~*P*M-allele vs. W-alleleMM vs. WWMW vs. WWMM+MW vs. WW148 C/T Total152909/29070.88 (0.77--0.99)0.0040.0410.82 (0.63--1.06)0.0070.1320.84 (0.75--0.95)0.1120.0040.82 (0.69--0.96)0.0220.015 Ethnicity  Asian102209/22260.85 (0.73--0.98)0.0160.0270.76 (0.57--1.03)0.0400.0780.84 (0.74--0.96)0.0740.0090.80 (0.66--0.96)0.0300.020  Caucasian4512/5820.85 (0.72--1.01)0.3800.0610.75 (0.53--1.07)0.3040.1080.77 (0.58--1.00)0.8960.0530.76 (0.59--0.98)0.7010.036  Latin1188/991.48 (1.05--2.09)--0.0262.64 (1.21--5.78)--0.0151.63 (0.84--3.13)--0.1461.86 (0.99--3.51)--0.054 Cancer type  LC41061/10470.74 (0.65--0.84)0.602\< 0.0010.53 (0.40--0.70)0.360\< 0.0010.76 (0.63--0.92)0.8650.0050.70 (0.59--0.84)0.803\< 0.001  CRC3411/3871.10 (0.90--1.35)0.0710.3481.36 (0.87--2.11)0.0960.1780.96 (0.68--1.34)0.1230.7961.01 (0.74--1.39)0.0600.932  PC2187/2000.83 (0.62--1.12)0.0990.2231.00 (0.54--1.87)0.5090.9870.54 (0.35--0.84)0.0880.0060.62 (0.41--0.93)0.0780.022  Others71250/12730.98 (0.87--1.11)0.2170.7510.98 (0.76--1.26)0.3630.8620.96 (0.80--1.15)0.3750.6400.96 (0.81--1.14)0.2180.664 Source  HB81684/17480.94 (0.85--1.04)0.0930.2190.89 (0.72--1.09)0.1280.2670.93 (0.80--1.09)0.5640.3640.92 (0.80--1.07)0.2680.272  PB71225/11590.82 (0.65--1.02)0.0090.0740.73 (0.44--1.22)0.0070.2350.74 (0.62--0.88)0.0830.0010.74 (0.56--0.97)0.0370.0321365 C/T Total4587/6050.71 (0.61--0.98)0.8730.0381.11 (0.34--3.70)--0.8590.63 (0.44--0.91)0.6680.0140.66 (0.47--0.94)0.7750.021 Ethnicity  Asian1303/3050.66 (0.43--0.99)--0.0431.11 (0.34--3.70)--0.8590.53 (0.32--0.86)--0.0100.58 (0.37--0.92)--0.020  Caucasian3284/3000.81 (0.47--1.38)0.8550.440NA0.80 (0.46--1.39)0.8460.4280.80 (0.46--1.39)0.8460.428 Cancer type  LC2403/4050.67 (0.46--0.97)0.8060.0341.11 (0.34--3.70)--0.8590.57 (0.37--0.87)0.5480.0090.61 (0.41--0.91)0.6690.016  PC184/1001.04 (0.37--2.94)--0.936NA1.05 (0.36--3.01)--0.9341.05 (0.36--3.01)--0.934  AT1100/1000.74 (0.30--1.79)--0.503NA0.73 (0.29--1.81)--0.4900.73 (0.29--1.81)--0.490rs4791171 A/G Total3785/4430.99 (0.85--1.17)0.7860.8640.94 (0.66--1.33)0.8730.7280.86 (0.62--1.17)0.5220.3220.89 (0.66--1.19)0.5750.429 Ethnicity  Asian1564/2501.00 (0.80--1.24)--0.9970.93 (0.69--1.48)--0.7730.84 (0.63--1.31)--0.4340.88 (0.68--1.34)--0.556  Arabian2221/1930.96 (0.73--1.27)0.5110.7780.96 (0.66--1.62)0.6030.8430.87 (0.56--1.36)0.2570.5380.89 (0.69--1.36)0.2940.596 Cancer type  BC199/830.87 (0.57--1.31)--0.4970.80 (0.35--1.84)--0.5990.65 (0.33--1.28)--0.2090.69 (0.36--1.31)--0.255  GBC1564/2501.00 (0.80--1.24)--0.9970.93 (0.59--1.48)--0.7730.84 (0.53--1.31)--0.4340.88 (0.58--1.34)--0.556  CRC1122/1101.04 (0.72--1.51)--0.8221.07 (0.53--2.17)--0.8541.09 (0.60--1.96)--0.7781.08 (0.63--1.87)--0.777*AT* astrocytoma, *BC* breast cancer, *CRC* colorectal cancer, *HB* hospital-based, *PB* population-based, *NA* not available, *LC* lung adenocarcinoma, *PC* prostate adenocarcinoma, *GBC* gallbladder cancer^a^*P* value of *Q*-test for heterogeneity test (*P*~heter~) Fig. 2Forest plot of cancer susceptibility correlated with *AXIN2* 148 C/T variant (heterozygote comparison of TC vs. CC, fixed-effects) in the stratified analyses by ethnicity Fig. 3Forest plot of TC versus CC genetic model of *AXIN2* 148 C/T polymorphism in the stratified analyses by cancer type (fixed-effects)

In silico analysis of *AXIN2* expression {#Sec11}
----------------------------------------

Results from in silico tools suggested that *AXIN2* expression in normal group was higher than that in lung adenocarcinoma tissue (Fig. [4](#Fig4){ref-type="fig"}a). However, no obvious difference was indicated for prostate adenocarcinoma (Fig. [4](#Fig4){ref-type="fig"}b). Moreover, we explored whether the *AXIN2* expression had an effect on the overall survival time of lung adenocarcinoma patients. However, Kaplan--Meier estimate showed no vital difference of overall survival time between high and low *AXIN2* expression groups (*P* = 0.40, Fig. [5](#Fig5){ref-type="fig"}).Fig. 4In silico analysis of *AXIN2* expressions in lung adenocarcinoma (**a**) and prostate adenocarcinoma (**b**) Fig. 5Association of *AXIN2* expression and the overall survival (OS) time among lung adenocarcinoma participants. Expression of *AXIN2* was decreased in lung adenocarcinoma tissue (**a**). However, no vital influence of overall survival time was indicated between high and low *AXIN2* expression groups (**b**, *P* \> 0.05)

Publication bias and sensitivity analyses {#Sec12}
-----------------------------------------

Egger's test and Begg's funnel plot were utilized to evaluate publication bias in all of enrolled studies. We demonstrated no publication bias for *AXIN2* 148 C/T polymorphism (allelic contrast, t = − 0.52, *P* = 0.614; TT vs. CC, t = − 0.66, *P* = 0.519; heterozygote comparison, t = − 0.30, *P* = 0.771; TT + TC vs. CC, t = − 0.34, *P* = 0.741), *AXIN2* 1365 C/T variant (allelic comparison, t = 2.20, *P* = 0.159; TC vs. CC, t = 2.18, *P* = 0.161) and rs4791171 A/G polymorphism (G-allele versus A-allele, t = − 0.55, *P* = 0.680; homozygote contrast, t = − 0.62, *P* = 0.645; GA vs. AA, t = − 0.72, *P* = 0.602; dominant model, t = − 0.78, *P* = 0.577). As shown in Fig. [6](#Fig6){ref-type="fig"}, results from funnel plots appeared symmetrical in the overall analysis under dominant model, which indicated a lack of publication bias. Sensitivity analyses were also utilized to assess the pooled OR by omission of any one study. The results suggested that the current data from pooled ORs were relatively stable. No single study can substantially change the overall OR (Fig. [7](#Fig7){ref-type="fig"}).Fig. 6Begg's funnel plot of publication bias for *AXIN2* 148 C/T (**a**), 1365 C/T (**b**), and rs4791171 A/G (**c**) under dominant model Fig. 7Sensitivity analyses about *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G variants and cancer risk (Dominant genetic model of MM + MW vs. WW). Leave-one-out sensitivity analyses were carried out to assess the stability of the overall results. No single study can substantially change the overall OR for *AXIN2* 148 C/T (**a**), 1365 C/T (**b**), and rs4791171 A/G (**c**) polymorphisms

Discussion {#Sec13}
==========

To date, large quantities of studies have been conducted to explore whether the variants confer individual's susceptibility to carcinoma. However, results from the previous publications have yielded controversial results \[[@CR21], [@CR22]\]. A previous study based on Indian descendants found a strong protective effect in participants having heterozygous genotype for 1365 C/T variant \[[@CR30]\], while another study group did not observe such positive correlation in Turkish population \[[@CR27]\]. In 2005, Wu et al. performed a meta-analysis and found that *AXIN2* rs2240308 variant may increase the risk of cancer, especially lung cancer in Asian descendants \[[@CR40]\]. Two years later, another meta-analysis indicated no obvious correlation between this variant and cancer risk in the overall analysis. Moreover, researches of this article observed that rs2240308 polymorphism was significantly associated with a decreased cancer risk in Asian population \[[@CR41]\]. The overall goal of the present study was to evaluate all eligible data based on the inclusion criteria to enhance the statistical powers and draw more accurate conclusions.

In the current study, a total of 4281 cases and 3955 control participants were investigated. The overall results showed evidence that *AXIN2* 148 C/T variant was associated with decreased cancer risk, especially for lung and prostate adenocarcinoma, which is in line with conclusions identified by Kanzaki et al. Liu et al. and Gune et al. \[[@CR19], [@CR26], [@CR28]\]. Similar results were observed in *AXIN2* 1365 C/T polymorphism (under allelic contrast, heterozygote comparison, and dominant genetic model). Moreover, in subgroup analysis by ethnicity, positive findings were obtained for Asian and Caucasian populations. In the stratified analysis by source of control, similar findings were identified in population-based studies for *AXIN2* 148 C/T variant, which is consistent with the findings reported by Yu et al. \[[@CR41]\]. Moreover, results from in silico tools showed that *AXIN2* expressions in lung cancer and prostate cancer are lower than that in normal counterpart. High expression of *AXIN2* may have longer OS time than low expression group for lung cancer participants, which were consistent with results derived from the present meta-analysis. Nevertheless, we indicated no significant difference between the high expression and low/medium expression of *AXIN2* in prostate cancer patients.

Some limitations of the above analysis should be mentioned. Firstly, the numbers of enrolled articles in the current analysis were still not large enough for the comprehensive analysis, especially for *AXIN2* 1365 C/T and rs4791171 A/G variants. Four articles towards *AXIN2* 1365 C/T and three articles for rs4791171 A/G polymorphism were eligible based on the selection criteria. Secondly, insufficient original data from the raw articles limited further evaluation of potential interactions, including relationship between the *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G variants and different tumor grade and stage. Thirdly, meta-analysis was based on unadjusted estimates, which may lead to serious confounding bias. Furthermore, gene--gene interaction would also participate in etiological mechanism of carcinoma. As shown in Fig. [8](#Fig8){ref-type="fig"}, at least 20 related genes may be involved in such interaction, which are required to be further investigated in future studies. On the other hand, core advantages in current analysis should also be acknowledged. Firstly, a comprehensive study of the correlation of the *AXIN2* 148 C/T, 1365 C/T, and rs4791171 A/G variants with overall cancer susceptibility is statistically more powerful than single case--control study. All the studies according to the inclusion criteria were accumulated in our analysis. Secondly, genotype distribution of controls is conformed to Hardy--Weinberg equilibrium (HWE) in any of the enrolled studies and no significant publication bias was found, which indicated that conclusions of the present analysis are relatively trustworthy.Fig. 8*AXIN2* correlations crosstalk with other genes determined by String server (Homo sapiens). 20 related genes could participate in the gene--gene interaction

Conclusions {#Sec14}
===========

Taken together, the current study showed evidence that *AXIN2* 148 C/T and 1365 C/T variants may be associated with decreased cancer susceptibility, especially for lung and prostate adenocarcinoma. Future large scale studies with standardized unbiased cases and well-matched control subjects are needed to ascertain these finding in more detail.
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